Smoking CessationNCT04798664
Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening
A study testing Removal of Financial Barriers, Financial Incentives and Mobile Health Application in people with Smoking Cessation, run by Abramson Cancer Center at Penn Medicine at 5 sites in United States.
Trial summary
To compare the effectiveness of four interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among underserved smokers referred for lung cancer screening at four large U.S. health systems. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Smoking Cessation
- What is being tested?
- Removal of Financial Barriers, Financial Incentives and Mobile Health Application
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,228 participants
- Where
- 5 sitesUnited States
- Study dates
- 17 May 2021to 29 Apr 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Current smoker (≥ 1 cigarettes per day, not including e-cigarettes)
- Has a low-dose computed tomography (LDCT) scan ordered by their physician
- Underserved, defined as one or more of the following: (a) Black, (b) Hispanic, (c) rural residence, or (d) low socioeconomic status (Defined as one or both of: high-school education or less, or household income <200% of the federal poverty line)
- Able to receive study invitation and screening, by virtue of showing up to a radiology location affiliated with a participating health system for the LDCT, or having a valid email address or telephone number on file with the health system
- Access to a cell phone with text messaging or the internet
- Aged 18 years or older
Who cannot join
- No cell phone
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United States5 sites
Geisinger
Danville, Pennsylvania, 17822
Henry Ford Health System
Detroit, Michigan, 48202
Lancaster General Health
Lancaster, Pennsylvania, 17601
Kaiser Permanente Southern California
Oakland, California, 94612
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
About this study
To compare the effectiveness of four interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among underserved smokers referred for lung cancer screening at four large U.S. health systems.
Read the detailed description
We will conduct a 4-arm randomized trial comparing 4 interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among smokers in underserved demographic groups. The 3,200 participants to be enrolled will be current smokers who are Black, Hispanic, and/or have low socioeconomic status (defined as household income <200% of the federal poverty line or a high school education or less) or rural residence who are referred for low-dose computed tomography (LDCT) screening at 4 large health systems. All adult patients with LDCT orders will be further screened for eligibility. Eligible patients will enroll with opt-out consent and complete the study using the NIH-funded Way to Health online research portal. The primary outcome will be biochemically confirmed, sustained abstinence from smoking tobacco for 6 months following participants' selected quit dates. Relapse rates will be tracked at 12 months.
- Conditions
- Smoking Cessation
- Being tested
- Removal of Financial Barriers, Financial Incentives, Mobile Health Application
- Keywords
- Patients, Underserved, Early Detection of Cancer, Lung Cancer, Nicotine Replacement Products, Incentives, Behavioral Economics, Smoking Cessation, Nicotine Dependence
- Medical subject headings
- Smoking Cessation, Lung Neoplasms, Tobacco Use Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Removal of Financial BarriersBehavioural
Also called NRT, Pharmacotherapy
Free access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications
Financial IncentivesBehavioural
Also called Incentives
Financial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months.
Mobile Health ApplicationBehavioural
Also called FutureMe
Episodic future thinking tool to overcome temporal discounting of future
| Study group | Role | What they receive |
|---|---|---|
| Basic Usual Care | No intervention | Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes. |
| Enhanced Usual Care | Active comparator | Participants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians. Receives: Behavioral: Removal of Financial Barriers |
| Enhanced Usual Care plus Financial Incentives | Active comparator | Participants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively. Receives: Behavioral: Removal of Financial Barriers; Behavioral: Financial Incentives |
| Enhanced Usual Care plus Financial Incentives plus Mobile Health Application | Active comparator | Participants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner. Receives: Behavioral: Removal of Financial Barriers; Behavioral: Financial Incentives; Behavioral: Mobile Health Application |
What is being measured
The primary outcome is the main question the study is designed to answer.
Biochemically Confirmed Smoking Abstinence Sustained for 6 Months
The primary outcome measure is sustained abstinence for 6 months, and will require self-report of smoking cessation followed by biochemical confirmation at 2 weeks, 3, and 6 months.
Measured: 6 months
Secondary outcomes (18)
Quit Status (Biochemically Confirmed)
Rates of sustained biochemically confirmed smoking cessation
Measured: 2 weeks, 3 months, 12 months
Health-related Quality of Life
The EuroQuol Group's quality of life (EQ-5D-5L) scale is a 25-item validated scale used to assess patients' perceived health-related quality of life across the domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Scale range: -1 to 1 index calculated from SAS package provided by author. Additionally calculating misery score which is sum of scores ranging from 5 to 25. For index, 1 is best possible health, while -1 are states worse than death. For the misery score, higher is worse health.
Measured: Baseline
Perceived Barriers to Cessation
The Challenges to Stopping Smoking Scale (CSS-21) is a validated 21-item measure to assess patients' perceived barriers to smoking cessation. The CSS-21 has two sub-scales: intrinsic factors (physical, psychological or cognitive aspects of quitting), 9 item intrinsic factors scale from 9-36, and extrinsic factors (social or environmental aspects of quitting), 12 item extrinsic factors scale from 12-43. Total score was also prepared, range 21-79. A higher score means a greater challenge.
Measured: Baseline
Self-efficacy Related to Cessation Efforts
We will use the 10-item situational measure of self-efficacy related to smoking behavior. This scale measures how sure participants are that they can avoid smoking in different situations. The scale ranges from 10-40, with a higher score demonstrating more self-efficacy.
Measured: Baseline
Motivation to Quit
The Stages of Change (SOC) is a validated 1-item measure to assess patient's self-reported motivation to quit.
Measured: Baseline
Temporal ("Delay") Discounting
Temporal discounting is a measure of impulsivity that reflects people's tendencies to discount the value of a reward as a function of how far in the future it would be received. We will use the 5-Trial Adjusting Delay Task to assess temporal discounting. The scale ranges from 0.000110 to 24, with a higher value meaning present is valued more over future gain. K values were calculated in R using the values noted in Koffarnus \& Bickel 2014.
Measured: Baseline
Health-related Quality of Life
The EuroQuol Group's quality of life (EQ-5D-5L) scale is a 25-item validated scale used to assess patients' perceived health-related quality of life across the domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Scale range: -1 to 1 index calculated from SAS package provided by author. Additionally calculating misery score which is sum of scores ranging from 5 to 25. For index, 1 is best possible health, while -1 are states worse than death. For the misery score, higher is worse health.
Measured: 6 months
Perceived Barriers to Cessation
The Challenges to Stopping Smoking Scale (CSS-21) is a validated 21-item measure to assess patients' perceived barriers to smoking cessation. The CSS-21 has two sub-scales: intrinsic factors (physical, psychological or cognitive aspects of quitting), 9 item intrinsic factors scale from 9-36, and extrinsic factors (social or environmental aspects of quitting), 12 item extrinsic factors scale from 12-43. Total score was also prepared, range 21-79. A higher score means a greater challenge.
Measured: 6 months
Self-efficacy Related to Cessation Efforts
We will use the 10-item situational measure of self-efficacy related to smoking behavior. This scale measures how sure participants are that they can avoid smoking in different situations. The scale ranges from 10-40, with a higher score demonstrating more self-efficacy.
Measured: 6 months
Motivation to Quit
The Stages of Change (SOC) is a validated 1-item measure to assess patient's self-reported motivation to quit.
Measured: 6 months
Temporal ("Delay") Discounting
Temporal discounting is a measure of impulsivity that reflects people's tendencies to discount the value of a reward as a function of how far in the future it would be received. We will use the 5-Trial Adjusting Delay Task to assess temporal discounting. The scale ranges from 0.000110 to 24, with a higher value meaning present is valued more over future gain. K values were calculated in R using the values noted in Koffarnus \& Bickel 2014.
Measured: 6 months
Health-related Quality of Life
The EuroQuol Group's quality of life (EQ-5D-5L) scale is a 25-item validated scale used to assess patients' perceived health-related quality of life across the domains of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Scale range: -1 to 1 index calculated from SAS package provided by author. Additionally calculating misery score which is sum of scores ranging from 5 to 25. For index, 1 is best possible health, while -1 are states worse than death. For the misery score, higher is worse health.
Measured: 12 months
Perceived Barriers to Cessation
The Challenges to Stopping Smoking Scale (CSS-21) is a validated 21-item measure to assess patients' perceived barriers to smoking cessation. The CSS-21 has two sub-scales: intrinsic factors (physical, psychological or cognitive aspects of quitting), 9 item intrinsic factors scale from 9-36, and extrinsic factors (social or environmental aspects of quitting), 12 item extrinsic factors scale from 12-43. Total score was also prepared, range 21-79. A higher score means a greater challenge.
Measured: 12 months
Self-efficacy Related to Cessation Efforts
We will use the 10-item situational measure of self-efficacy related to smoking behavior. This scale measures how sure participants are that they can avoid smoking in different situations. The scale ranges from 10-40, with a higher score demonstrating more self-efficacy.
Measured: 12 months
Motivation to Quit
The Stages of Change (SOC) is a validated 1-item measure to assess patient's self-reported motivation to quit.
Measured: 12 months
Temporal ("Delay") Discounting
Temporal discounting is a measure of impulsivity that reflects people's tendencies to discount the value of a reward as a function of how far in the future it would be received. We will use the 5-Trial Adjusting Delay Task to assess temporal discounting. The scale ranges from 0.000110 to 24, with a higher value meaning present is valued more over future gain. K values were calculated in R using the values noted in Koffarnus \& Bickel 2014.
Measured: 12 months
Self-report Cigarette Abstinence
Rates of sustained self-reported cigarette abstinence
Measured: 2 weeks, 3 months, 6 months, 12 months
Self-report Other Tobacco Abstinence
Rates of sustained self-reported other tobacco abstinence
Measured: 2 weeks, 3 months, 6 months, 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Mar 2021
- Study start17 May 2021
- Primary completion4 Nov 2024
- Study completion29 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Smoking CessationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a prospective randomized controlled trial using opt-out consent with longitudinal follow-up of patients over 12 months. Based on the expected accrual at each of the four health systems, we expect that overall there will be 470 participants in basic usual care (Arm 1), and 910 participants in each of intervention arms 2-4.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 3,228 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute
- Responsible party
- Sponsor
- Investigators
- Scott D Halpern, MD PhD, Principal investigator, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04798664
- Sponsor's protocol ID
- UPCC 12519
- Status last verified
- Feb 2026
- First submitted
- 11 Mar 2021
- Last updated
- 25 Feb 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie published results will be made available to other researchers, after de-identification.
Publications
Hart JL, Vachani A, Neslund-Dudas CM, Gould MK, Facktor MA, Blady S, Bayes BA, Sheu D, Madden VL, Ferrante EB, Patel N, Tian J, Whitman C, Creekmur B, Kohn R, Simoff MJ, Volpp KG, Small D, Scott ME, Holm AL, Stephens Shields AJ, Halpern SD. Smoking Cessation Among Underserved Patients Referred for Lung Cancer Screening: A Randomized Clinical Trial. JAMA. 2026 Oct 5. doi: 10.1001/jama.2026.17192. Online ahead of print.
PubMed 42832220Kohn R, Vachani A, Small D, Stephens-Shields AJ, Sheu D, Madden VL, Bayes BA, Chowdhury M, Friday S, Kim J, Gould MK, Ismail MH, Creekmur B, Facktor MA, Collins C, Blessing KK, Neslund-Dudas CM, Simoff MJ, Alleman ER, Epstein LH, Horst MA, Scott ME, Volpp KG, Halpern SD, Hart JL; Stakeholder Advisory Committee. Comparing Smoking Cessation Interventions among Underserved Patients Referred for Lung Cancer Screening: A Pragmatic Trial Protocol. Ann Am Thorac Soc. 2022 Feb;19(2):303-314. doi: 10.1513/AnnalsATS.202104-499SD.
PubMed 34384042
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening
- ClinicalTrials.gov ID
- NCT04798664
- Acronym / sponsor ID
- UPCC 12519
- Conditions
- Smoking Cessation
- Keywords
- Patients, Underserved, Early Detection of Cancer, Lung Cancer, Nicotine Replacement Products, Incentives, Behavioral Economics, Smoking Cessation, Nicotine Dependence
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3,228 participants (actual)
- Lead sponsor
- Abramson Cancer Center at Penn MedicineUniversity, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute
- Study start
- 17 May 2021 (actual)
- Primary completion
- 4 Nov 2024 (actual)
- Study completion
- 29 Apr 2025 (actual)
- First posted
- 15 Mar 2021 (actual)
- Results
- Posted 25 Feb 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare the effectiveness of four interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among underserved smokers referred for lung cancer screening at four large U.S. health systems.
Detailed description
We will conduct a 4-arm randomized trial comparing 4 interventions to promote sustained, biochemically confirmed smoking abstinence for 6 months among smokers in underserved demographic groups. The 3,200 participants to be enrolled will be current smokers who are Black, Hispanic, and/or have low socioeconomic status (defined as household income <200% of the federal poverty line or a high school education or less) or rural residence who are referred for low-dose computed tomography (LDCT) screening at 4 large health systems. All adult patients with LDCT orders will be further screened for eligibility. Eligible patients will enroll with opt-out consent and complete the study using the NIH-funded Way to Health online research portal. The primary outcome will be biochemically confirmed, sustained abstinence from smoking tobacco for 6 months following participants' selected quit dates. Relapse rates will be tracked at 12 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 4
- Model description
- This is a prospective randomized controlled trial using opt-out consent with longitudinal follow-up of patients over 12 months. Based on the expected accrual at each of the four health systems, we expect that overall there will be 470 participants in basic usual care (Arm 1), and 910 participants in each of intervention arms 2-4.
| Arm | Type | Receives |
|---|---|---|
| Basic Usual Care | No intervention | –Participants receive the usual care approach, Ask-Advise-Refer (AAR), which is a standard approach in which non-study clinicians ask smokers about their desire to quit smoking, advise them to quit, and provide informational resources such as hotlines, specialized clinics, or smoking cessation classes. |
| Enhanced Usual Care | Active comparator | Behavioral: Removal of Financial BarriersParticipants receive the basic usual care of Ask-Advise-Refer as well as free access to nicotine replacement therapy (NRT) and/or reimbursement of up to $300 for any smoking cessation medications (varenicline/Chantix or bupropion/Zyban) prescribed by non-study clinicians. |
| Enhanced Usual Care plus Financial Incentives | Active comparator | Behavioral: Removal of Financial Barriers, Behavioral: Financial IncentivesParticipants receive all aspects of enhanced usual care plus an incentive plan in which they will be informed of their eligibility to earn $100, $200, and $300 if they submit negative tests for nicotine metabolites at 2 weeks, 3 month and 6 months following their quit date, respectively. |
| Enhanced Usual Care plus Financial Incentives plus Mobile Health Application | Active comparator | Behavioral: Removal of Financial Barriers, Behavioral: Financial Incentives, Behavioral: Mobile Health ApplicationParticipants receive all aspects of Arm 3 plus an intervention to promote episodic future thinking (EFT), called FutureMe. EFT has been shown to reliably reduce discounting of the future. Patients will practice using EFT cues to envision the "future is now" between the time of enrollment and the quit date, and will then receive cues from the quit date through the end of the intervention period, 6 months later, unless they ask to stop receiving cues sooner. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Current smoker (≥ 1 cigarettes per day, not including e-cigarettes)
- Has a low-dose computed tomography (LDCT) scan ordered by their physician
- Underserved, defined as one or more of the following: (a) Black, (b) Hispanic, (c) rural residence, or (d) low socioeconomic status (Defined as one or both of: high-school education or less, or household income <200% of the federal poverty line)
- Able to receive study invitation and screening, by virtue of showing up to a radiology location affiliated with a participating health system for the LDCT, or having a valid email address or telephone number on file with the health system
- Access to a cell phone with text messaging or the internet
Key exclusion criteria (1 listed)
- No cell phone
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Removal of Financial BarriersAlso: NRT, PharmacotherapyFree access to nicotine replacement therapies and/or reimbursement for smoking cessation prescription medications | Behavioural | Enhanced Usual Care, Enhanced Usual Care plus Financial Incentives, Enhanced Usual Care plus Financial Incentives plus Mobile Health Application |
| Financial IncentivesAlso: IncentivesFinancial incentive plan of up to $600 for biochemically-confirmed, sustained abstinence for 6 months. | Behavioural | Enhanced Usual Care plus Financial Incentives, Enhanced Usual Care plus Financial Incentives plus Mobile Health Application |
| Mobile Health ApplicationAlso: FutureMeEpisodic future thinking tool to overcome temporal discounting of future | Behavioural | Enhanced Usual Care plus Financial Incentives plus Mobile Health Application |
Primary outcome
Biochemically Confirmed Smoking Abstinence Sustained for 6 Months
Time frame: 6 months
The primary outcome measure is sustained abstinence for 6 months, and will require self-report of smoking cessation followed by biochemical confirmation at 2 weeks, 3, and 6 months.
18 secondary outcomes
Quit Status (Biochemically Confirmed)
Time frame: 2 weeks, 3 months, 12 months
Health-related Quality of Life
Time frame: Baseline
Perceived Barriers to Cessation
Time frame: Baseline
Self-efficacy Related to Cessation Efforts
Time frame: Baseline
Motivation to Quit
Time frame: Baseline
Temporal ("Delay") Discounting
Time frame: Baseline
Health-related Quality of Life
Time frame: 6 months
Perceived Barriers to Cessation
Time frame: 6 months
Self-efficacy Related to Cessation Efforts
Time frame: 6 months
Motivation to Quit
Time frame: 6 months
Temporal ("Delay") Discounting
Time frame: 6 months
Health-related Quality of Life
Time frame: 12 months
Perceived Barriers to Cessation
Time frame: 12 months
Self-efficacy Related to Cessation Efforts
Time frame: 12 months
Motivation to Quit
Time frame: 12 months
Temporal ("Delay") Discounting
Time frame: 12 months
Self-report Cigarette Abstinence
Time frame: 2 weeks, 3 months, 6 months, 12 months
Self-report Other Tobacco Abstinence
Time frame: 2 weeks, 3 months, 6 months, 12 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42832220Hart JL, Vachani A, Neslund-Dudas CM, Gould MK, Facktor MA, Blady S, Bayes BA, Sheu D, Madden VL, Ferrante EB, Patel N, Tian J, Whitman C, Creekmur B, Kohn R, Simoff MJ, Volpp KG, Small D, Scott ME, Holm AL, Stephens Shields AJ, Halpern SD. Smoking Cessation Among Underserved Patients Referred for Lung Cancer Screening: A Randomized Clinical Trial. JAMA. 2026 Oct 5. doi: 10.1001/jama.2026.17192. Online ahead of print.
- Derived from this study: PubMed 34384042Kohn R, Vachani A, Small D, Stephens-Shields AJ, Sheu D, Madden VL, Bayes BA, Chowdhury M, Friday S, Kim J, Gould MK, Ismail MH, Creekmur B, Facktor MA, Collins C, Blessing KK, Neslund-Dudas CM, Simoff MJ, Alleman ER, Epstein LH, Horst MA, Scott ME, Volpp KG, Halpern SD, Hart JL; Stakeholder Advisory Committee. Comparing Smoking Cessation Interventions among Underserved Patients Referred for Lung Cancer Screening: A Pragmatic Trial Protocol. Ann Am Thorac Soc. 2022 Feb;19(2):303-314. doi: 10.1513/AnnalsATS.202104-499SD.
- Individual participant dataSharing planned: Yes. Individual participant data that underlie published results will be made available to other researchers, after de-identification.
Related trials for Smoking Cessation
Active, not recruiting
An Interactive Smartphone Application to Motivate Smokers to Quit
Smoking Cessation, Smoking Behaviors
Not yet recruiting
Comparing the Efficacy of a Conversational Agent (QuitBot) Versus Standard Health Education on Smoking Cessation Among Medical Students; A Randomized Controlled Trial.
Conversational Agent, Smoking Cessation
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Active, not recruitingPhase 3
Early Withdrawal Exposure and Negative Affect Withdrawal (NAW) Regulation Training for Smoking Cessation
Tobacco Dependence
Active, not recruitingEarly Phase 1
Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer
Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Scott D Halpern, MD PhD principal investigator
University of Pennsylvania
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Removal of Financial Barriers, Financial Incentives and Mobile Health Application in people with Smoking Cessation, run by Abramson Cancer Center at Penn Medicine at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 25 Feb 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Biochemically Confirmed Smoking Abstinence Sustained for 6 Months (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04798664, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.